Institutional Fund
Blue Owl Capital Holdings LP
New York, NYCIK 18587036 filings on record
Portfolio Value
$372.17M
Q1 2026
Holdings
75
Reported positions
New Buys
20
Opened this quarter
QoQ Change
+14.9%
from $324.04M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Aktis Oncology Inc15.2%
- Larimar Therapeutics Inc8.6%
- Engene Holdings Inc8.1%
- Nuveen Churchill Direct Lend7.3%
- Cullinan Therapeutics Inc7.3%
- Blue Owl Capital Corporation6.1%
- Other47.4%
Portfolio Holdings
75 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Aktis Oncology Inc | 3.16M | $56.56M | 15.2% | +3.16M | New |
| 2 | Larimar Therapeutics Inc | 7.12M | $32.04M | 8.6% | +296.3K | Added |
| 3 | Engene Holdings Inc | 4.42M | $30.08M | 8.1% | +1.06M | Added |
| 4 | Nuveen Churchill Direct Lend | 2.14M | $27.27M | 7.3% | 0 | Held |
| 5 | Cullinan Therapeutics Inc | 1.91M | $27.14M | 7.3% | −441.2K | Reduced |
| 6 | Blue Owl Capital Corporation | 2.05M | $22.62M | 6.1% | 0 | Held |
| 7 | Maplight Therapeutics Inc | 1.01M | $20.45M | 5.5% | +678.9K | Added |
| 8 | Compass Therapeutics Inc | 2.94M | $15.56M | 4.2% | −525.0K | Reduced |
| 9 | Context Therapeutics Inc | 5.09M | $13.33M | 3.6% | −2.34M | Reduced |
| 10 | Holley Inc | 4.24M | $13.01M | 3.5% | +90.3K | Added |
65 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio